5.21.26
NEWS & EVENTS
What’s “c/λ” at Accent?
News
4.17.26
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
4.2.26
Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
10.22.25
Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10.8.25
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
5.22.25
Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting
4.28.25
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
4.15.25